U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H16N3O7S2.Na
Molecular Weight 449.434
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CEFOXITIN SODIUM

SMILES

[Na+].[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@]2(NC(=O)CC3=CC=CS3)OC)C([O-])=O

InChI

InChIKey=GNWUOVJNSFPWDD-XMZRARIVSA-M
InChI=1S/C16H17N3O7S2.Na/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19;/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22);/q;+1/p-1/t14-,16+;/m1./s1

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C16H16N3O7S2
Molecular Weight 426.444
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/cefoxitin.html

Cefoxitin is a cephamycin antibiotic often grouped with the second-generation cephalosporins. It is active against a broad range of gram-negative bacteria including anaerobes. The methoxy group in the 7a position provides cefoxitin with a high degree of stability in the presence of beta-lactamases, both penicillinases and cephalosporinases, of gram-negative bacteria. The bactericidal action of cefoxitin results from inhibition of cell wall synthesis.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Klebsiella pneumoniae growth
Target ID: P08506
Gene ID: 945455.0
Gene Symbol: dacC
Target Organism: Escherichia coli (strain K12)
Target ID: P0AEB2
Gene ID: 945222.0
Gene Symbol: dacA
Target Organism: Escherichia coli (strain K12)
Target ID: P0AFI5
Gene ID: 946662.0
Gene Symbol: pbpG
Target Organism: Escherichia coli (strain K12)
Target ID: P02919
Gene ID: 944843.0
Gene Symbol: mrcB
Target Organism: Escherichia coli (strain K12)
Target ID: P0A3M6
Gene ID: 933948.0
Gene Symbol: penA
Target Organism: Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
8.0 nM [IC50]
Target ID: Q8DR59
Gene ID: 934791.0
Gene Symbol: pbpA
Target Organism: Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
6.8 nM [IC50]
Target ID: 933569.0
Gene Symbol: pbp2a
2.4 nM [IC50]
Target ID: 934893.0
Gene Symbol: pbp1b
0.145 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Cefoxitin

Approved Use

Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections, including pneumonia and lung abscess, caused by Streptococcus pneumoniae, other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli, Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli, Klebsiella species, Proteus mirabilis, Morganella morganii, Proteus vulgaris and Providencia species (including P. rettgeri). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli, Klebsiella species, Bacteroides species including Bacteroides fragilis, and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli, Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis, Clostridium species, Peptococcus niger, Peptostreptococcus species and Streptococcus agalactiae. Cefoxitin for injection, like cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when Cefoxitin for injection is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae, Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli, Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis, Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis]), Escherichia coli, Proteus mirabilis, Klebsiella species, Bacteroides species including B. fragilis, Clostridium species, Peptococcus niger, and Peptostreptococcus species.

Launch Date

2010
Curative
Cefoxitin

Approved Use

Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections, including pneumonia and lung abscess, caused by Streptococcus pneumoniae, other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli, Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli, Klebsiella species, Proteus mirabilis, Morganella morganii, Proteus vulgaris and Providencia species (including P. rettgeri). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli, Klebsiella species, Bacteroides species including Bacteroides fragilis, and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli, Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis, Clostridium species, Peptococcus niger, Peptostreptococcus species and Streptococcus agalactiae. Cefoxitin for injection, like cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when Cefoxitin for injection is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae, Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli, Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis, Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis]), Escherichia coli, Proteus mirabilis, Klebsiella species, Bacteroides species including B. fragilis, Clostridium species, Peptococcus niger, and Peptostreptococcus species.

Launch Date

2010
Curative
Cefoxitin

Approved Use

Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections, including pneumonia and lung abscess, caused by Streptococcus pneumoniae, other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli, Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli, Klebsiella species, Proteus mirabilis, Morganella morganii, Proteus vulgaris and Providencia species (including P. rettgeri). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli, Klebsiella species, Bacteroides species including Bacteroides fragilis, and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli, Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis, Clostridium species, Peptococcus niger, Peptostreptococcus species and Streptococcus agalactiae. Cefoxitin for injection, like cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when Cefoxitin for injection is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae, Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli, Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis, Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis]), Escherichia coli, Proteus mirabilis, Klebsiella species, Bacteroides species including B. fragilis, Clostridium species, Peptococcus niger, and Peptostreptococcus species.

Launch Date

2010
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
24 μg/mL
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CEFOXITIN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
33.5 μg × h/mL
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CEFOXITIN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.67 h
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CEFOXITIN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
27%
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CEFOXITIN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 g single, intramuscular
Dose: 2 g
Route: intramuscular
Route: single
Dose: 2 g
Sources:
unhealthy, 17 years
n = 1
Health Status: unhealthy
Age Group: 17 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Hoigne's syndrome...
AEs leading to
discontinuation/dose reduction:
Hoigne's syndrome (1 patient)
Sources:
12 g 1 times / day multiple, intravenous
Highest studied dose
Dose: 12 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 g, 1 times / day
Sources:
unhealthy, 22 years
n = 1
Health Status: unhealthy
Condition: bacterial endocarditis
Age Group: 22 years
Sex: M
Population Size: 1
Sources:
2 g 3 times / day multiple, intravenous
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 45 years
n = 1
Health Status: unhealthy
Age Group: 45 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Hemolytic anemia...
AEs leading to
discontinuation/dose reduction:
Hemolytic anemia (1 patient)
Sources:
1 g 4 times / day multiple, intravenous
Dose: 1 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 4 times / day
Sources:
unhealthy, 77 years
n = 1
Health Status: unhealthy
Condition: peritonitis
Age Group: 77 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Hemolytic anemia, Pancytopenia...
AEs leading to
discontinuation/dose reduction:
Hemolytic anemia (1 patient)
Pancytopenia (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Hoigne's syndrome 1 patient
Disc. AE
2 g single, intramuscular
Dose: 2 g
Route: intramuscular
Route: single
Dose: 2 g
Sources:
unhealthy, 17 years
n = 1
Health Status: unhealthy
Age Group: 17 years
Sex: F
Population Size: 1
Sources:
Hemolytic anemia 1 patient
Disc. AE
2 g 3 times / day multiple, intravenous
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 45 years
n = 1
Health Status: unhealthy
Age Group: 45 years
Sex: F
Population Size: 1
Sources:
Hemolytic anemia 1 patient
Disc. AE
1 g 4 times / day multiple, intravenous
Dose: 1 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 4 times / day
Sources:
unhealthy, 77 years
n = 1
Health Status: unhealthy
Condition: peritonitis
Age Group: 77 years
Sex: M
Population Size: 1
Sources:
Pancytopenia 1 patient
Disc. AE
1 g 4 times / day multiple, intravenous
Dose: 1 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 4 times / day
Sources:
unhealthy, 77 years
n = 1
Health Status: unhealthy
Condition: peritonitis
Age Group: 77 years
Sex: M
Population Size: 1
Sources:
PubMed

PubMed

TitleDatePubMed
Ceftizoxime-induced hemolysis due to immune complexes: case report and determination of the epitope responsible for immune complex-mediated hemolysis.
1999 Mar
Occurrence and transferability of beta-lactam resistance in Enterobacteriaceae isolated in Children's University Hospital in Bratislava.
2001
[Occurrence of beta-lactamase type ESBL and IBL in Pseudomonas aeruginosa rods].
2001
Occurrence of metronidazole and imipenem resistance among Bacteroides fragilis group clinical isolates in Hungary.
2001
Improved methods for detection of methicillin-resistant Staphylococcus aureus.
2001 Apr
Clinical features of patients with invasive Eikenella corrodens infections and microbiological characteristics of the causative isolates.
2001 Apr
[Staphylococcus aureus: new detection of intrinsic resistance using the diffusion method].
2001 Apr
Mechanism of reaction of acyl phosph(on)ates with the beta-lactamase of Enterobacter cloacae P99.
2001 Apr 17
[Clostridium difficile diarrhea: frequency of detection in a medical center in Buenos Aires, Argentina].
2001 Apr-Jun
A novel metallo-beta-lactamase, Mbl1b, produced by the environmental bacterium Caulobacter crescentus.
2001 Dec 14
Nosocomial bloodstream infection in pediatric patients: Siriraj Hospital, Bangkok; 1996-1999.
2001 Feb
A randomised controlled trial of antibiotic prophylaxis in elective caesarean delivery.
2001 Feb
Anti-anaerobic activity of antibacterial agents.
2001 Feb
Plasmid-mediated and inducible cephalosporinase DHA-2 from Klebsiella pneumoniae.
2001 Feb
Possible asymptomatic carrier of salmonella typhimurium in the preputium: a case report.
2001 Jan-Mar
Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies.
2001 Jul
Inactivation of Aeromonas hydrophila metallo-beta-lactamase by cephamycins and moxalactam.
2001 Jul
Detection of beta-lactamase-mediated resistance.
2001 Jul
Susceptibility of the Bacteroides fragilis group to newer quinolones and other standard anti-anaerobic agents.
2001 Jul
Antibiotic therapy in intra-abdominal infections--a review on randomised clinical trials.
2001 Jul 30
Antibacterial effect of antibiotic solution on cellular viability in canine veins.
2001 Jun
Antimicrobial resistance surveillance of bacteria in 1999 in Korea with a special reference to resistance of enterococci to vancomycin and gram-negative bacilli to third generation cephalosporin, imipenem, and fluoroquinolone.
2001 Jun
Interaction energies between beta-lactam antibiotics and E. coli penicillin-binding protein 5 by reversible thermal denaturation.
2001 Jun
Antimicrobial resistance of Shigella sonnei in Korea during the last two decades.
2001 Mar
Influence of in-vivo endotoxin liberation on anti-anaerobic antimicrobial efficacy.
2001 Oct
Probing substrate binding to metallo-beta-lactamase L1 from Stenotrophomonas maltophilia by using site-directed mutagenesis.
2002
Klebsiella pneumoniae: epidemiology and analysis of risk factors for infections caused by resistant strains.
2002 Aug
Cross-reactivity of cefotetan and ceftriaxone antibodies, associated with hemolytic anemia, with other: cephalosporins and penicillin.
2002 Aug
[Identification of plasmid-encoded cephalosporinase ACC-1 among various enterobacteria (Klebsiella pneumoniae, Proteus mirabilis, Salmonella) isolated from a Tunisian hospital (Sfax 997-2000)].
2002 Feb
Multicentre evaluation of the VITEK 2 Advanced Expert System for interpretive reading of antimicrobial resistance tests.
2002 Feb
[Extended-spectrum beta-lactamase detection in Enterobacteriaceae and antibiotic susceptibility analysis].
2002 Feb 28
Primary liver abscess caused by one clone of Klebsiella pneumoniae with two colonial morphotypes and resistotypes.
2002 Jan
Occurrence and characterization of resistance to extended-spectrum cephalosporins mediated by beta-lactamase CMY-2 in Salmonella isolated from food-producing animals in Canada.
2002 Jul
Characterization of cefotaxime-resistant Escherichia coli isolates from a nosocomial outbreak at three geriatric hospitals.
2002 Jun
Outbreak of multidrug-resistant Salmonella newport--United States, January-April 2002.
2002 Jun 28
Escherichia coli isolated from seafood: toxicity and plasmid profiles.
2002 Mar
A pathway-specific cell based screening system to detect bacterial cell wall inhibitors.
2002 Mar
[Genotypic exploration of a hospital neonatal outbreak due to Klebsiella pneumoniae producing extended-spectrum-betalactamase].
2002 May
Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial.
2002 May
Rapidly growing members of the genus Mycobacterium affecting dogs and cats.
2002 May-Jun
Further modification of the Hodge test to screen AmpC beta-lactamase (CMY-1)-producing strains of Escherichia coli and Klebsiella pneumoniae.
2002 Nov
[Trends in antimicrobial utilization in a university hospital, 1990-1996].
2002 Oct
[Activity of 14 antimicrobials against Eikenella corrodens].
2002 Oct-Dec
Natural antibiotic susceptibility of Enterobacter amnigenus, Enterobacter cancerogenus, Enterobacter gergoviae and Enterobacter sakazakii strains.
2002 Sep
Klebsiella and enterobacter: antibiotic resistance and treatment implications.
2002 Sep
Selection of cefoxitin-resistant bacteroides thetaiotaomicron mutants and mechanisms involved in beta-lactam resistance.
2002 Sep 1
Natural antimicrobial susceptibilities of strains of 'unusual' Serratia species: S. ficaria, S. fonticola, S. odorifera, S. plymuthica and S. rubidaea.
2003 Apr
Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease.
2003 Jan-Feb
Emergence of ceftriaxone-resistant Salmonella isolates and rapid spread of plasmid-encoded CMY-2-like cephalosporinase, Taiwan.
2003 Mar
Beta-lactamase characterization in Escherichia coli isolates with diminished susceptibility or resistance to extended-spectrum cephalosporins recovered from sick animals in Spain.
2003 Summer
Patents

Sample Use Guides

In Vivo Use Guide
Adults The usual adult dosage range is 1 gram to 2 grams every six to eight hours.
Route of Administration: Intravenous
CEFOXITIN inhibited Mycobacterium fortuitum growth with MIC 32 ug/ml
Substance Class Chemical
Created
by admin
on Sat Dec 16 07:44:02 GMT 2023
Edited
by admin
on Sat Dec 16 07:44:02 GMT 2023
Record UNII
Q68050H03T
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CEFOXITIN SODIUM
EP   JAN   MART.   ORANGE BOOK   USAN   USP   VANDF   WHO-DD  
USAN  
Official Name English
CEFOXITIN SODIUM [MART.]
Common Name English
Sodium (6R,7S)-3-(hydroxymethyl)-7-methoxy-8-oxo-7-[2-(2-thienyl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate carbamate (ester)
Common Name English
CEFOXITIN SODIUM [VANDF]
Common Name English
CEFOXITIN SODIUM [JAN]
Common Name English
MEFOXIN
Brand Name English
CEFOXITIN SODIUM SALT [MI]
Common Name English
CEFOXITIN SODIUM SALT
MI  
Common Name English
CEFOXITIN SODIUM [USP IMPURITY]
Common Name English
CEFOXITIN SODIUM [ORANGE BOOK]
Common Name English
CEFOXITIN SODIUM [USP MONOGRAPH]
Common Name English
Cefoxitin sodium [WHO-DD]
Common Name English
CEFOXITIN SODIUM [USAN]
Common Name English
5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 3-(((AMINOCARBONYL)OXY)METHYL)-7-METHOXY-8-OXO-7-((2-THIENYLACETYL)AMINO)-, SODIUM SALT, (6R-CIS)-
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C357
Created by admin on Sat Dec 16 07:44:03 GMT 2023 , Edited by admin on Sat Dec 16 07:44:03 GMT 2023
Code System Code Type Description
FDA UNII
Q68050H03T
Created by admin on Sat Dec 16 07:44:03 GMT 2023 , Edited by admin on Sat Dec 16 07:44:03 GMT 2023
PRIMARY
SMS_ID
100000076312
Created by admin on Sat Dec 16 07:44:03 GMT 2023 , Edited by admin on Sat Dec 16 07:44:03 GMT 2023
PRIMARY
NCI_THESAURUS
C28915
Created by admin on Sat Dec 16 07:44:03 GMT 2023 , Edited by admin on Sat Dec 16 07:44:03 GMT 2023
PRIMARY
DAILYMED
Q68050H03T
Created by admin on Sat Dec 16 07:44:03 GMT 2023 , Edited by admin on Sat Dec 16 07:44:03 GMT 2023
PRIMARY
ECHA (EC/EINECS)
251-574-6
Created by admin on Sat Dec 16 07:44:03 GMT 2023 , Edited by admin on Sat Dec 16 07:44:03 GMT 2023
PRIMARY
EVMPD
SUB13277MIG
Created by admin on Sat Dec 16 07:44:03 GMT 2023 , Edited by admin on Sat Dec 16 07:44:03 GMT 2023
PRIMARY
PUBCHEM
23667300
Created by admin on Sat Dec 16 07:44:03 GMT 2023 , Edited by admin on Sat Dec 16 07:44:03 GMT 2023
PRIMARY
ChEMBL
CHEMBL996
Created by admin on Sat Dec 16 07:44:03 GMT 2023 , Edited by admin on Sat Dec 16 07:44:03 GMT 2023
PRIMARY
EPA CompTox
DTXSID8048995
Created by admin on Sat Dec 16 07:44:03 GMT 2023 , Edited by admin on Sat Dec 16 07:44:03 GMT 2023
PRIMARY
RXCUI
203118
Created by admin on Sat Dec 16 07:44:03 GMT 2023 , Edited by admin on Sat Dec 16 07:44:03 GMT 2023
PRIMARY RxNorm
CAS
33564-30-6
Created by admin on Sat Dec 16 07:44:03 GMT 2023 , Edited by admin on Sat Dec 16 07:44:03 GMT 2023
PRIMARY
DRUG BANK
DBSALT001211
Created by admin on Sat Dec 16 07:44:03 GMT 2023 , Edited by admin on Sat Dec 16 07:44:03 GMT 2023
PRIMARY
MERCK INDEX
m3208
Created by admin on Sat Dec 16 07:44:03 GMT 2023 , Edited by admin on Sat Dec 16 07:44:03 GMT 2023
PRIMARY Merck Index
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
USP
IMPURITY -> PARENT
ONE OF THE ISOMER (R) OF CEFOXITIN SODIUM IMPURITY B [EP IMPURITY]
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
USP
Related Record Type Details
ACTIVE MOIETY